ALIVUS Alivus Life Q2 FY25 results (Jul–Sep 2024) and concall
Glenmark Life Sciences faced a challenging Q2 FY25 due to a temporary production halt at its Ankleshwar facility and market softness in Argentina, leading to a 14.9% YoY revenue decline. However, the company demonstrated strong margin resilience, with gross margins reaching 55.6% driven by a favorable product mix. Management remains optimistic about a stronger H2 FY25, supported by new launches and a robust CDMO pipeline, despite revising full-year revenue guidance downward to high single digits.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 507 |
| EBITDA | 134 |
| Net profit | 95 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
